Connect your AI

Upstream Bio, Inc. UPB Change in receivables

Change in receivables at other companies

Ethos Technologies, Inc. LIFE

-$396K+47.1%

MoonLake ImmunotherapeuticsMLTX

$894K+512%

BioCryst PharmaceuticalsBCRX

$474K-96.6%

Other financials

Income statement

Revenue$1.0M+82.7%

Operating income-$43.6M-36.2%

Net income-$40.6M-48.8%

EPS (diluted)-$0.75-47.1%

Balance sheet

Cash & equivalents$96.7M+35.6%

Total debt$1.1M-34.5%

Total equity$304.0M-31.8%

Total assets$318.1M-30.3%

Cash flow

Operating cash flow-$47.9M-16.2%

CapEx$54.0K-70.8%

Free cash flow-$30.7M-55.0%

Valuation

Market cap$346.11M-40.9%

Enterprise value$250.5M-51.4%

P/S104.2×-151×

Profitability

Operating margin-5,176.5%+1,764pp

Net margin-4,719%+2,752pp

Returns & leverage

Return on equity-41.8%—

Debt / equity0×0.0×

Current ratio23.1×-24.3×

Where this comes from

Reported directly by Upstream Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsAndNotesReceivable.

The official record: Upstream Bio, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Upstream Bio, Inc.'s change in receivables.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Upstream Bio, Inc.'s change in receivables?: Upstream Bio, Inc. (UPB) reported change in receivables of $366K in Q1 2026.
How has Upstream Bio, Inc.'s change in receivables changed year-over-year?: Upstream Bio, Inc.'s change in receivables increased by 878.7% year-over-year, from -$47K to $366K.
What does change in receivables mean?: Change in total receivables including trade and non-trade receivables.